Skip to main content

General Rheumatology

      #Sjogren disease is here to stay.
      “The name has caught up to the science of SD and this can translate to better treat

      sheila RHEUMarampa

      1 week 3 days ago
      #Sjogren disease is here to stay. “The name has caught up to the science of SD and this can translate to better treatment outcomes for patients” - Dr. Bryant England #ACR25 @RheumNow https://t.co/M4r0XXkswv
      Basic Sci Year in Review:
      Dr. Anne Davidson discusses the potential pathologic link bet tryptophan, indole, I3S & I

      sheila RHEUMarampa

      1 week 3 days ago
      Basic Sci Year in Review: Dr. Anne Davidson discusses the potential pathologic link bet tryptophan, indole, I3S & IL-17 pathways. I3S induces epidermal thickening in mice and correlated with dse activity in patients with #psoriasis #ACR25 @RheumNow https://t.co/WNNbBBESQ3
      Fatigue is one of the most disabling symptoms in psoriatic arthritis (PsA), yet its causes are often underexplored. At ACR 2025, Abstract #0549, a possible hidden contributor was studied: obstructive sleep apnea (OSA).
      With increased disease awareness and more regular, accessible testing for anti-neutrophil cytoplasmic antibodies (ANCA), ANCA-associated vasculitis (AAV) has become an increasingly recognized clinical entity in rheumatologic practice. 
      From Eye on Cytokine Storm- Decoding MAS by Dr Grant Schulert : “IL-18 is highly elevated in SJIa and other autoinflam

      Gabriela Martinez Zayas, MD MartinezZayasMd

      1 week 4 days ago
      From Eye on Cytokine Storm- Decoding MAS by Dr Grant Schulert : “IL-18 is highly elevated in SJIa and other autoinflammatory disorders…can amplify innate signaling as well as induce IFN-gamma”. @RheumNow #ACR2025 https://t.co/6e5yfeDepX
      🔥 Hot off the press

      Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which sec

      Mrinalini Dey DrMiniDey

      1 week 4 days ago
      🔥 Hot off the press Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which secukinumab met all primary endpoints in treatment of PMR. https://t.co/RlcQWybKrR #ACR25 @RheumNow https://t.co/ucNt2HxJpW
      ×